[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$forLTCmZvBAl4uCpe2xW_FttXBsZ_9wbdNdJ5MBOvrBY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"University of Jena",[4],89,false,3,6,214411,5,73,[14,16,18,21,24,26,28,30],{"name":15,"count":9},"Cystic Fibrosis",{"name":17,"count":11},"Hypercholesterolemia",{"name":19,"count":20},"Healthy",4,{"name":22,"count":23},"Age Related Maculopathy",2,{"name":25,"count":23},"Sinusitis",{"name":27,"count":23},"Pseudomonas Aeruginosa",{"name":29,"count":23},"Hypertriglyceridemia",{"name":31,"count":23},"Rheumatoid Arthritis",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT04902937","Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.","2026-12-31","neoadjuvant and adjuvant chemotherapy",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03906292","Frontline Asciminib Combination in Chronic Phase CML","2027-12","Imatinib",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,90,108,126,144,166,194,212,230,254,279,297,322,340,366,392,416,440,464,489,514,541,566],{"intervention":52,"totalTrials":23,"cells":53},"dasatinib",{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":73,"PHASE4":86,"NA":88},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":72,"soonestReadout":41},[61],{"nctId":39,"briefTitle":40,"status":62,"phases":63,"primaryCompletion":41,"completion":41,"start":64,"enrollment":65,"conditions":66,"interventions":68},"ACTIVE_NOT_RECRUITING",[46],"2019-08-19",125,[67],"Chronic Myeloid Leukemia",[42,69,70,71],"Nilotinib 300 mg","Dasatinib","Asciminib",1,{"trials":74,"activeCount":56},[75],{"nctId":76,"briefTitle":77,"status":78,"phases":79,"primaryCompletion":80,"completion":80,"start":81,"enrollment":82,"conditions":83,"interventions":85},"NCT02890784","Dasatinib Holiday for Improved Tolerability","COMPLETED",[47],"2023-03-31","2016-08",291,[84],"Myeloid Leukemia, Chronic",[52],{"trials":87,"activeCount":56},[],{"trials":89,"activeCount":56},[],{"intervention":42,"totalTrials":72,"cells":91},{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":102,"PHASE4":104,"NA":106},{"trials":93,"activeCount":56},[],{"trials":95,"activeCount":56},[],{"trials":97,"activeCount":72,"soonestReadout":41},[98],{"nctId":39,"briefTitle":40,"status":62,"phases":99,"primaryCompletion":41,"completion":41,"start":64,"enrollment":65,"conditions":100,"interventions":101},[46],[67],[42,69,70,71],{"trials":103,"activeCount":56},[],{"trials":105,"activeCount":56},[],{"trials":107,"activeCount":56},[],{"intervention":69,"totalTrials":72,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":111,"activeCount":56},[],{"trials":113,"activeCount":56},[],{"trials":115,"activeCount":72,"soonestReadout":41},[116],{"nctId":39,"briefTitle":40,"status":62,"phases":117,"primaryCompletion":41,"completion":41,"start":64,"enrollment":65,"conditions":118,"interventions":119},[46],[67],[42,69,70,71],{"trials":121,"activeCount":56},[],{"trials":123,"activeCount":56},[],{"trials":125,"activeCount":56},[],{"intervention":71,"totalTrials":72,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":138,"PHASE4":140,"NA":142},{"trials":129,"activeCount":56},[],{"trials":131,"activeCount":56},[],{"trials":133,"activeCount":72,"soonestReadout":41},[134],{"nctId":39,"briefTitle":40,"status":62,"phases":135,"primaryCompletion":41,"completion":41,"start":64,"enrollment":65,"conditions":136,"interventions":137},[46],[67],[42,69,70,71],{"trials":139,"activeCount":56},[],{"trials":141,"activeCount":56},[],{"trials":143,"activeCount":56},[],{"intervention":37,"totalTrials":72,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":156},{"trials":147,"activeCount":56},[],{"trials":149,"activeCount":56},[],{"trials":151,"activeCount":56},[],{"trials":153,"activeCount":56},[],{"trials":155,"activeCount":56},[],{"trials":157,"activeCount":72,"soonestReadout":36},[158],{"nctId":34,"briefTitle":35,"status":159,"phases":160,"primaryCompletion":36,"completion":36,"start":161,"enrollment":162,"conditions":163,"interventions":165},"RECRUITING",[],"2021-07-01",200,[164],"Tumor Cell, Circulating",[37],{"intervention":167,"totalTrials":72,"cells":168},"Amisulpride",{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":192},{"trials":170,"activeCount":56},[],{"trials":172,"activeCount":56},[],{"trials":174,"activeCount":56},[],{"trials":176,"activeCount":56},[],{"trials":178,"activeCount":56},[179],{"nctId":180,"briefTitle":181,"status":182,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT00419653","Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy","TERMINATED",[48],"2007-09","2003-01",19,[188],"Schizophrenia",[167,190,191],"Olanzapine","Haloperidol",{"trials":193,"activeCount":56},[],{"intervention":190,"totalTrials":72,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":210},{"trials":197,"activeCount":56},[],{"trials":199,"activeCount":56},[],{"trials":201,"activeCount":56},[],{"trials":203,"activeCount":56},[],{"trials":205,"activeCount":56},[206],{"nctId":180,"briefTitle":181,"status":182,"phases":207,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":208,"interventions":209},[48],[188],[167,190,191],{"trials":211,"activeCount":56},[],{"intervention":191,"totalTrials":72,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":56},[],{"trials":217,"activeCount":56},[],{"trials":219,"activeCount":56},[],{"trials":221,"activeCount":56},[],{"trials":223,"activeCount":56},[224],{"nctId":180,"briefTitle":181,"status":182,"phases":225,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":226,"interventions":227},[48],[188],[167,190,191],{"trials":229,"activeCount":56},[],{"intervention":231,"totalTrials":72,"cells":232},"Pulmozyme",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":250,"NA":252},{"trials":234,"activeCount":56},[],{"trials":236,"activeCount":56},[],{"trials":238,"activeCount":56},[],{"trials":240,"activeCount":56},[241],{"nctId":242,"briefTitle":243,"status":78,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":11,"conditions":247,"interventions":249},"NCT00265434","Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis",[47],"2006-05","2005-12",[15,248],"Chronic Rhinosinusitis",[231],{"trials":251,"activeCount":56},[],{"trials":253,"activeCount":56},[],{"intervention":255,"totalTrials":72,"cells":256},"Peginterferon α2b",{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":275,"NA":277},{"trials":258,"activeCount":56},[],{"trials":260,"activeCount":56},[],{"trials":262,"activeCount":56},[],{"trials":264,"activeCount":56},[265],{"nctId":266,"briefTitle":267,"status":78,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT01657604","TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study",[47],"2022-05-31","2012-08-24",717,[67],[255,274],"Nilotinib",{"trials":276,"activeCount":56},[],{"trials":278,"activeCount":56},[],{"intervention":274,"totalTrials":72,"cells":280},{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":293,"NA":295},{"trials":282,"activeCount":56},[],{"trials":284,"activeCount":56},[],{"trials":286,"activeCount":56},[],{"trials":288,"activeCount":56},[289],{"nctId":266,"briefTitle":267,"status":78,"phases":290,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":291,"interventions":292},[47],[67],[255,274],{"trials":294,"activeCount":56},[],{"trials":296,"activeCount":56},[],{"intervention":298,"totalTrials":72,"cells":299},"Dornase alfa",{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":318,"NA":320},{"trials":301,"activeCount":56},[],{"trials":303,"activeCount":56},[],{"trials":305,"activeCount":56},[],{"trials":307,"activeCount":56},[308],{"nctId":309,"briefTitle":310,"status":78,"phases":311,"primaryCompletion":312,"completion":312,"start":184,"enrollment":313,"conditions":314,"interventions":316},"NCT00534079","Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis",[47],"2009-02",23,[15,315],"Rhinosinusitis",[298,317],"isotonic saline",{"trials":319,"activeCount":56},[],{"trials":321,"activeCount":56},[],{"intervention":317,"totalTrials":72,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":336,"NA":338},{"trials":325,"activeCount":56},[],{"trials":327,"activeCount":56},[],{"trials":329,"activeCount":56},[],{"trials":331,"activeCount":56},[332],{"nctId":309,"briefTitle":310,"status":78,"phases":333,"primaryCompletion":312,"completion":312,"start":184,"enrollment":313,"conditions":334,"interventions":335},[47],[15,315],[298,317],{"trials":337,"activeCount":56},[],{"trials":339,"activeCount":56},[],{"intervention":341,"totalTrials":72,"cells":342},"conventional vs. flexible, intensive insulin therapy",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":362,"NA":364},{"trials":344,"activeCount":56},[],{"trials":346,"activeCount":56},[],{"trials":348,"activeCount":56},[],{"trials":350,"activeCount":56},[351],{"nctId":352,"briefTitle":353,"status":354,"phases":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},"NCT00440284","Flexible, Intensive vs. Conventional Insulin Therapy in Insulin-Naive Adults With Type 2 Diabetes","UNKNOWN",[47],"2004-12","2004-01",38,[360],"Type 2 Diabetes",[341],{"trials":363,"activeCount":56},[],{"trials":365,"activeCount":56},[],{"intervention":367,"totalTrials":72,"cells":368},"Fragmin P Forte",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":388,"NA":390},{"trials":370,"activeCount":56},[],{"trials":372,"activeCount":56},[],{"trials":374,"activeCount":56},[],{"trials":376,"activeCount":56},[377],{"nctId":378,"briefTitle":379,"status":78,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT00400387","Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss",[47],"2012-12","2013-04","2006-11",449,[386],"Abortion, Habitual",[367],{"trials":389,"activeCount":56},[],{"trials":391,"activeCount":56},[],{"intervention":393,"totalTrials":72,"cells":394},"Tobramycin",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":410,"PHASE4":412,"NA":414},{"trials":396,"activeCount":56},[],{"trials":398,"activeCount":56},[],{"trials":400,"activeCount":56},[401],{"nctId":402,"briefTitle":403,"status":78,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":409},"NCT00774072","Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization",[46],"2010-11","2008-10",9,[15,27],[393],{"trials":411,"activeCount":56},[],{"trials":413,"activeCount":56},[],{"trials":415,"activeCount":56},[],{"intervention":417,"totalTrials":72,"cells":418},"Midostaurin",{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":420,"activeCount":56},[],{"trials":422,"activeCount":56},[],{"trials":424,"activeCount":56},[425],{"nctId":426,"briefTitle":427,"status":182,"phases":428,"primaryCompletion":429,"completion":429,"start":430,"enrollment":72,"conditions":431,"interventions":433},"NCT03951961","Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation",[46],"2021-02-28","2020-03-20",[432],"Acute Myeloid Leukemia, Adult",[417],{"trials":435,"activeCount":56},[],{"trials":437,"activeCount":56},[],{"trials":439,"activeCount":56},[],{"intervention":441,"totalTrials":72,"cells":442},"Colistin",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":444,"activeCount":56},[],{"trials":446,"activeCount":56},[],{"trials":448,"activeCount":56},[449],{"nctId":450,"briefTitle":451,"status":78,"phases":452,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":457},"NCT01035853","Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization",[46],"2012-04","2009-12",10,[15,27],[441],{"trials":459,"activeCount":56},[],{"trials":461,"activeCount":56},[],{"trials":463,"activeCount":56},[],{"intervention":465,"totalTrials":72,"cells":466},"PETN",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":468,"activeCount":56},[],{"trials":470,"activeCount":56},[],{"trials":472,"activeCount":56},[473],{"nctId":474,"briefTitle":475,"status":78,"phases":476,"primaryCompletion":477,"start":478,"enrollment":479,"conditions":480,"interventions":482},"NCT01355822","Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies",[45,46],"2008-01","2002-04",111,[481],"High Risk Pregnancy",[465],{"trials":484,"activeCount":56},[],{"trials":486,"activeCount":56},[],{"trials":488,"activeCount":56},[],{"intervention":490,"totalTrials":72,"cells":491},"Ruxolitinib",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":493,"activeCount":56},[],{"trials":495,"activeCount":56},[],{"trials":497,"activeCount":56},[498],{"nctId":499,"briefTitle":500,"status":78,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},"NCT04338958","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation",[46],"2021-07-15","2020-04-22",193,[506],"Covid-19",[490],{"trials":509,"activeCount":56},[],{"trials":511,"activeCount":56},[],{"trials":513,"activeCount":56},[],{"intervention":515,"totalTrials":72,"cells":516},"Diclofenac",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":518,"activeCount":56},[],{"trials":520,"activeCount":56},[],{"trials":522,"activeCount":56},[],{"trials":524,"activeCount":56},[],{"trials":526,"activeCount":56},[],{"trials":528,"activeCount":56},[529],{"nctId":530,"briefTitle":531,"status":78,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":540},"NCT06251349","Comparative Analysis of Radiotherapeutic and Medical Procedures for the Prophylaxis of Heterotopic Ossifications",[],"2023-12-31","2013-01-01",512,[537,538,539],"Heterotopic Ossification","Hip Arthropathy","Myositis Ossificans Traumatica, Thigh",[515],{"intervention":542,"totalTrials":72,"cells":543},"sodium chloride 6%",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":554},{"trials":545,"activeCount":56},[],{"trials":547,"activeCount":56},[],{"trials":549,"activeCount":56},[],{"trials":551,"activeCount":56},[],{"trials":553,"activeCount":56},[],{"trials":555,"activeCount":56},[556],{"nctId":557,"briefTitle":558,"status":78,"phases":559,"primaryCompletion":382,"completion":560,"start":561,"enrollment":562,"conditions":563,"interventions":564},"NCT01086839","Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis",[49],"2013-06","2010-03",69,[15,315],[542,565],"sodium chloride 0,9%",{"intervention":565,"totalTrials":72,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":578},{"trials":569,"activeCount":56},[],{"trials":571,"activeCount":56},[],{"trials":573,"activeCount":56},[],{"trials":575,"activeCount":56},[],{"trials":577,"activeCount":56},[],{"trials":579,"activeCount":56},[580],{"nctId":557,"briefTitle":558,"status":78,"phases":581,"primaryCompletion":382,"completion":560,"start":561,"enrollment":562,"conditions":582,"interventions":583},[49],[15,315],[542,565]]